Rovast

Management of hyperlipidaemias, including primary hypercholesterolaemia (type IIa), mixed dyslipidaemia (type IIb), & hypertriglyceridaemia (type IV). HoFH.

Initially 5-10 mg in the evening, may be adjusted at interval of not <4 wk up to max of 80 mg once daily in 3 divided doses of 20 mg, 20 mg & evening dose of 40 mg. Patient w/ ischaemic heart disease May be given an initial dose of 20 mg. Patient taking ciclosporin, fibric acid derivatives or nicotinic acid Max: 10 mg daily.

May be taken with or without food.

Hypersensitivity. Patients w/ active liver disease or w/ unexplained persistent elevations of serum transaminases. Pregnancy & lactation.

Discontinue use if marked or persistent increases in serum-aminotransferase conc occur; markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily w/hold treatment in any patient w/ acute, serious condition suggestive of myopathy or predisposing to development of renal failure secondary to rhabdomyolysis eg, sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic endocrine, & electrolyte disorders, or uncontrolled seizures. Not to be used in patients who already have unexplained persistently raised serum-aminotransferase conc. Patients who have history of liver disease &/or consume substantial quantities of alcohol; predisposing factors for myopathy eg, renal impairment, advanced age & inadequately treated hyperthyroidism. Avoid combination therapy w/ gemfibrozil. Risk of myopathy during treatment may be increased w/ concurrent administration of other lipid-lowering therapies, ciclosporin, or lopinavir/ritonavir.

GI disturbances; headache, skin rashes, dizziness, blurred vision, insomnia & dysgeusia.

Increased conc w/ ciclosporin or gemfibrozil

Dyslipidaemic Agents

C10AA07 - rosuvastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.

Rx